Background
Introduction
Alemtuzumab is a humanized, rat IgG1κ monoclonal antibody directed against the CD52 cellsurface antigen. CD52 is a glycoprotein expressed on approximately 95% of peripheral blood lymphocytes, natural killer (NK) cells, monocytes, macrophages, and thymocytes [1] . Lymphocyte depletion is expected to increase the risk of opportunistic infections [2, 3] . However, some studies have shown that the frequency of infectious diseases does not increase after organ transplantation [4] [5] [6] [7] [8] [9] [10] .
For short-term induction therapy with alemtuzumab following liver transplantation, we found that T-and B-cell numbers declined rapidly after alemtuzumab therapy; however, the NK cell number was unchanged (S1 Fig) . Similar results were previously reported for kidney transplantation [2, 3] . Therefore, we hypothesized that NK cells have an important role in resisting microbial attack during alemtuzumab induction for several months while T-cells repopulate. A clinical examination of some patients who underwent organ transplantation revealed that NK cells reconstitute the blood earlier than T-and B-cells after alemtuzumab treatment [5, 7] . The two mechanisms described above might offer a partial explanation of why lymphocyte depletion with alemtuzumab did not increase the incidence of serious viral infections following organ transplantation.
NK cells are important effectors of innate immunity and are identified phenotypically as CD3 − CD56 + [4] . NK cells are functionally characterized by their ability to eliminate pathogeninfected cells and tumor cells without prior sensitization. This is achieved through the release of granules containing perforin and granzyme, and pro-inflammatory cytokines, especially interferon (IFN)-γ [5] . NK cells are abundant in the liver, in contrast to their relatively minor presence in peripheral lymphatics and other lymphatic organs in both rodents [6] [7] [8] [9] and humans [10, 11] . In addition, liver NK cells differ from peripheral NK cells with regard to cytotoxicity toward cancer cells [10] and protection against viruses [12, 13] . In preliminary data, we fortuitously found that the liver contains a high amount of CD52 − NK cells, and we hypothesized that liver NK cells were refractory to alemtuzumab treatment because of their CD52 negativity.
In this study, we investigated the effect of alemtuzumab on the cell death of NK cells at a clinically relevant concentration, and characterized CD52 − NK cells by examining cytotoxicity toward tumor cells and IFN-γ production in vitro by using purified NK cells, especially from the liver.
Materials and Methods

Mononuclear cell preparation
The written informed consent for use of non-transplanted tissue for research and/or educational purposes from the donor or the next of kin was obtained. None of the transplant donors were from a vulnerable population and all donors or next of kin provided written informed consent that was freely given. The institutional review board of the University of Miami, School of Medicine approved this study. Peripheral blood (40 mL) and liver graft perfusate (2 L) samples were obtained from deceased liver transplant donors at the time of organ procurement. Liver mononuclear cells (LMNCs) were isolated from the liver graft perfusate, as previously described, because the proportions of LMNCs extracted from liver perfusates were almost identical to those collected using enzymatic dissociation [10, 11] . LMNCs and peripheral blood mononuclear cells (PBMCs) were isolated by gradient centrifugation with Ficoll-Hypaque (GE Healthcare, Pittsburgh, PA, USA).
Flow cytometry
Flow cytometry (FCM) analyses were performed using an LSR II flow cytometer and BD ACCURI C6 (BD Biosciences, San Jose, CA, USA). The following monoclonal antibodies (mAbs) were used for surface staining of the lymphocytes: FITC-conjugated anti-CD3 (HIT3a; BD), anti-CD56 (B159; BD), anti-CD16 (3G8: BD), anti-CD94 (HP-3D9; BD), and anti-CD52 (HI186: BioLegend); PE-conjugated anti-CD52 (HI186: BioLegend), anti-NKp30 (P30-15; BioLegend), anti-NKp44 (P44-8.1; BD), anti-NKp46(BAB281; BECKMAN COULTER), anti-CD226 (11A8; BioLegend), anti-CD69 (FN50; BD), anti-TRAIL (RIK-2; BD), antiCD107a (H4A3; BD), and anti-NKG2D (1D11; BioLegend); PerCP-conjugated anti-CD3 (SK7; BD), APC-conjugated anti-CD56 (B159; BD), APC-eFluor780-conjugated CD3 (UCHT1, eBioscience, San Diego, CA, USA), and eFluor 605NC-conjugated anti-CD16 (eBioCB16; eBioscience). Dead cells were excluded by light scattering and 4 0 6-diamidino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA) staining. Lymphocyte IFN-γ production was measured using a combination of cell surface and cytoplasmic mAb stains according to the manufacturer's instructions. Briefly, 4 h after treatment with Leukocyte Activation Cocktail (BD GolgiPlug; BD), the cells were fixed and permeabilized with Cytofix/Cytoperm solution (BD) and washed with Perm/Wash Buffer (BD). Subsequently, aliquots were stained with mAbs against intracellular cytokines or anti-IFN-γ-PE (BD). FCM analyses were performed with the FlowJo software (Tree Star, Ashland, OR, USA).
Detection of cell death after co-incubation with alemtuzumab
The viability of the residual cells was determined by FCM using the Annexin V-FITC Apoptosis Detection Kit (BD). The reagents were used according to the manufacturer's protocol. LMNCs and PBMCs were exposed to various concentrations of alemtuzumab (0, 0.1, 1, 10, and 100 μg/mL) in RPMI 1640 medium without complement for different time periods (1 and 4 h).
After the incubation period, cells were stained with 1 μL Annexin V solution and 5 μL propidium iodide solution for FCM analysis. Viable cells were negative for both Annexin V and propidium iodide. Dead cells were double positive for Annexin V and propidium iodide. We observed that Annexin V single positive cells were undergoing apoptosis.
Isolation of NK cells
+ NK cells were purified from LMNCs by magnetic cell sorting using the human NK cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer's instructions. The CD52 subsets of NK cells were sorted from purified NK cells with a BD FACS-Aria cell sorter (BD) using anti-CD3 (HIT3a; BD), anti-CD56 (B159; BD), and anti-CD52 (YTH34.5; AbD Serotec). Post-sorting purities were consistently >97%. NK subsets were then used for cytotoxicity and IFN-γ production assays. NK cell subsets were cultured in Dulbecco's Modified Eagle Medium (Invitrogen) supplemented with 25 mmol/L HEPES buffer (Invitrogen), 10% heat-inactivated fetal bovine serum (Mediatech, Manassas, VA, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (Thermo Scientific, Waltham, MA, USA) (complete medium) with 1000 U/mL interleukin (IL)-2 (Proleukin, Novartis, Emeryville, CA, USA) for 2 days.
NK cytotoxicity
The cell cytotoxicity assay was performed by FCM, as previously described [11] . Briefly, the target cells were labeled with 0.1 μM Vybrant 1 CFDA SE Cell Tracer (Life Technologies, Carlsbad, CA, USA) for 5 min at 37°C in 5% CO 2 . The labeled cells were washed twice in PBS, resuspended in complete medium, and counted using trypan blue staining. The effector cells were coincubated at various ratios with target cells for 1 h at 37°C in 5% CO 2 . As a control, either target cells or effector cells were incubated alone in complete medium to measure spontaneous cell death. DAPI was added to every tube. Data were analyzed using FlowJo software (Tree Star). Cytotoxicity was calculated as a percentage using the following formula: % cytotoxicity = [(% experimental DAPI + dead targets) − (% spontaneous DAPI + dead targets)]/[(100 − (% spontaneous DAPI + dead targets)] × 100.
ELISA
IFN-γ production of NK cell subsets during culture was measured by ELISA (BioLegend). The supernatants were collected after incubation and stored at −80°C until further use. The IFN-γ ELISA was performed according to the manufacturer's instructions.
Statistical analysis
Data were presented as mean ± SD. The statistical differences of the results were analyzed by 2-tailed Student's t-test (2 groups) or by analysis of variance (ANOVA) followed by a Tukey post-test (more than 2 groups), using the SPSS Statistics Version 22 for Windows (IBM Corp., Armonk, NY, USA). P values of 0.05 or less were considered statistically significant.
Results
The liver contained a large number of CD52 − NK cells
To analyze whether alemtuzumab affected NK cells, we collected PBMCs and LMNCs by gradient centrifugation from 7 organ donors. LMNCs were isolated from the liver graft perfusate. The proportion of LMNCs extracted from the liver perfusate was almost identical to that of LMNCs collected by enzymatic dissociation, as previously reported [10, 11] . First, CD52 expression of the cells was analyzed by FCM, because alemtuzumab is an antibody that directly binds the CD52 cell-surface antigen. CD52 expression on LMNCs was significantly lower than that on PBMCs (p< 0.05) (Fig 1A) . Although almost all liver lymphocytes (T-cells, B-cells, and NKT cells) expressed CD52, only approximately 30% of liver NK cells expressed CD52 (29.0% ± 11.5). This value was significantly lower than that for peripheral blood NK cells (69.9% ± 7.6) (Fig 1C) .
Liver NK cells survived even after co-incubation with alemtuzumab
To analyze the difference in susceptibility to alemtuzumab between PBMCs and LMNCs in vitro, the cells were treated with various concentrations of alemtuzumab (0, 0.1, 1, 10, and 100 μg/mL) for different time periods (1 h and 4 h). Co-incubation with alemtuzumab induced cell death in PBMCs in a dose-dependent manner. However, under the same conditions, most LMNCs survived even with co-incubation with alemtuzumab. The survival rate of LMNCs after co-incubation with alemtuzumab was significantly higher than that of PBMCs, at every concentration (Fig 2A) . As NK cells comprised a large proportion of LMNCs and most of them were CD52-negative, we wondered whether liver NK cells were less susceptible than liver non-NK cells. As shown in Fig 2B, − NK cells, we tested the cytotoxicity and IFN-γ production of the CD52 fraction sorted from the liver NK cells (Fig 4A) . This fraction was cultured with IL-2 for 2 days, and cytotoxicity was analyzed in an FCM-based assay. tumor cells compared with CD52 + NK cells (Fig 4B) . We analyzed the IFN-γ levels secreted into the supernatant and found that compared with CD52 + NK cells, CD52 − NK cells cocultured with IL-2 produced 20-fold more IFN-γ (Fig 4C) . Using intracellular FCM, we confirmed that CD52 − NK cells were the only source of IFN-γ (Fig 4D) .
Discussion
In this study, we showed that CD52 expression on NK cells was lower than that of other lymphocyte groups (S2 Fig) . These findings are compatible with those in a report by Rao et al. [14] . Interestingly, we also found that compared to peripheral blood, the human liver contained a larger number of CD52 − NK cells, which cannot be targeted by alemtuzumab treatment because of the inability of alemtuzumab to bind. We also showed that liver NK cells exhibited decreased susceptibility to alemtuzumab compared with other lymphocytes in vitro (Fig 2B) . These findings indicate that liver NK cells might survive even after alemtuzumab-based lymphocyte depletion following organ transplantation. This is important because liver NK cells simultaneously contribute to innate protective functions against microbes while contributing to liver parenchymal cell protection against immune damage. Every tissue in our body consists of a unique microenvironment that can differentially shape immune reactivity. The liver immune environment is unique because it is continually exposed to gut-derived antigens [15] , which may have a role in endowing the liver with some immune privilege [16] . On the other hand, liver NK cells contribute to the protection of liver parenchymal cells against immune damage. The intrinsic "activation" of adaptive and innate cells within the liver may reflect this dual role of ensuring tissue immune privilege and offering antimicrobial protection. The prior exposure of liver innate immune cells to gut-derived microbial products may, in part, explain the altered NK cell phenotypes and behavior in liver NK cells. Most of the CD56 bright liver NK cells did not express CD52 on the cell surface (Fig 1C) . Rao et al. observed the same phenomenon for peripheral blood NK cells, a minor population of PBMCs [14] . In a model of transgenic mice expressing human CD52, splenic NK cells expressed little CD52, and lymphocyte depletion was not as profound in lymphoid organs [17] . In humans, CD52 is not expressed on peripheral blood dendritic cells. Similarly, epidermal and small intestinal dendritic cells did not express CD52 and were therefore unlikely to be depleted by alemtuzumab treatment [18] . In our in vitro study, LMNCs, which contain abundant numbers present the proportion of each subset. The dot plots are representative of 7 independent experiments (alemtuzumab; 100 μg/ mL, 4-h culture). The bar graphs show the mean survival rate ± SD of LMNCs and PBMCs after 4-h treatment at each concentration (n = 7, *p < 0.05 by Student's t-test). (B) The survival rate of liver NK cells was significantly higher than that of liver-derived non-NK cells (n = 4, *p < 0.05 by Student's t-test). (C) CD56 bright NK cells survived after co-incubation with alemtuzumab, compared to CD56 dim NK cells (n = 4, *p < 0.05 by Student's t-test).
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− NK cells, appeared relatively resistant to alemtuzumab, whereas circulating PBMCs were depleted in a dose-dependent manner (Fig 2A) . Even addition of 20% autologous serum, as a source of complement during the alemtuzumab exposure in vitro did not increase cell death of liver. There is however, good evidence that the major mechanism of alemtuzumabbased lymphocyte depletion is ADCC [19] . Although other interpretations are possible, our results suggest that liver NK cells express little CD52, and are therefore relatively unaffected by Supporting Information Author Contributions
